CL2021002252A1 - Composición farmacéutica que comprende paracetamol e ibuprofeno - Google Patents

Composición farmacéutica que comprende paracetamol e ibuprofeno

Info

Publication number
CL2021002252A1
CL2021002252A1 CL2021002252A CL2021002252A CL2021002252A1 CL 2021002252 A1 CL2021002252 A1 CL 2021002252A1 CL 2021002252 A CL2021002252 A CL 2021002252A CL 2021002252 A CL2021002252 A CL 2021002252A CL 2021002252 A1 CL2021002252 A1 CL 2021002252A1
Authority
CL
Chile
Prior art keywords
ibuprofen
paracetamol
pharmaceutical composition
acetaminophen
disclosed
Prior art date
Application number
CL2021002252A
Other languages
English (en)
Inventor
Maura Murphy
Matt Callahan
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of CL2021002252A1 publication Critical patent/CL2021002252A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formas de dosificación orales sólidas que contienen 325 mg de acetaminofeno y 97,5 mg de ibuprofeno o 500 mg de acetaminofeno y 150 mg de ibuprofeno, en donde el ibuprofeno tiene un [D50] entre 1 y 9 μm.
CL2021002252A 2019-02-27 2021-08-26 Composición farmacéutica que comprende paracetamol e ibuprofeno CL2021002252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16/287,836 US11197830B2 (en) 2019-02-27 2019-02-27 Pharmaceutical composition containing acetaminophen and ibuprofen

Publications (1)

Publication Number Publication Date
CL2021002252A1 true CL2021002252A1 (es) 2022-04-29

Family

ID=72140141

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002252A CL2021002252A1 (es) 2019-02-27 2021-08-26 Composición farmacéutica que comprende paracetamol e ibuprofeno

Country Status (23)

Country Link
US (4) US11197830B2 (es)
EP (1) EP3930691A4 (es)
CN (1) CN113795243A (es)
AU (4) AU2019268077B2 (es)
BR (1) BR112021017037A2 (es)
CA (1) CA3131917A1 (es)
CL (1) CL2021002252A1 (es)
CO (1) CO2021011525A2 (es)
CR (1) CR20210451A (es)
EA (1) EA202192118A1 (es)
EC (1) ECSP21072036A (es)
GB (1) GB2595406B (es)
IL (1) IL285866A (es)
JO (1) JOP20210235A1 (es)
MA (2) MA62176A1 (es)
MX (1) MX2021010338A (es)
NZ (1) NZ759337A (es)
PE (1) PE20220591A1 (es)
SG (1) SG11202109258WA (es)
TN (1) TN2021000176A1 (es)
TW (1) TW202045148A (es)
UA (1) UA127775C2 (es)
WO (1) WO2020176736A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11918693B2 (en) * 2019-06-27 2024-03-05 Haleon Us Holdings Llc Ibuprofen and acetaminophen tablet

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5148139B2 (es) 1972-09-30 1976-12-18
AU605538B2 (en) 1988-01-19 1991-01-17 Adcock Ingram Limited Pharmaceutical unit
CA1336687C (en) 1989-08-23 1995-08-15 Thomas M. Tencza Process for preparing tablets containing ibuprofen, apap and caffeine, the products of this process and the use of such products
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5260337A (en) 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
JP3982889B2 (ja) 1997-11-28 2007-09-26 あすか製薬株式会社 イブプロフェン含有医薬製剤
US6440983B1 (en) 2000-12-21 2002-08-27 Mary Theresa Frank-Kollman Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers
CN100360117C (zh) * 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
GB0414442D0 (en) 2004-06-28 2004-07-28 Borealis As Zeolite catalysts
US20080275125A1 (en) * 2004-07-07 2008-11-06 Aft Pharmaceuticals Limited Combination Composition
KR20060072839A (ko) 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
GB0519350D0 (en) 2005-09-22 2005-11-02 Boots Healthcare Int Ltd Therapeutic agents
WO2008079818A2 (en) 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
JP5148139B2 (ja) 2007-03-12 2013-02-20 パナソニック株式会社 半導体装置及びその製造方法
WO2009012590A1 (en) * 2007-07-23 2009-01-29 Kingsway Pharmaceuticals Inc. Therapeutic formulations for the treatment of cold and flu-like symptoms
US20090264530A1 (en) 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
JP2012505830A (ja) 2008-10-14 2012-03-08 エイエフティ ファーマスーティカルズ リミテッド 医薬品及び医薬品治療
KR101873500B1 (ko) 2009-04-24 2018-08-02 아이슈티카 피티와이 리미티드 생물학적 활성 물질의 용해 프로파일 개선방법
CA2759125C (en) 2009-04-24 2017-08-15 Iceutica Pty Ltd A novel formulation of indomethacin
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
SG186388A1 (en) 2010-07-07 2013-01-30 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
CL2010000738A1 (es) 2010-07-08 2011-03-25 Wockhardt Res Centre Suspension farmaceutica oral que comprende desde 100 hasta 500 mg/5ml de paracetamol, desde 40 hasta 80 mg/5ml de ibuprofeno o desde 200 hasta 400 mg/5ml de paracetamol, desde 100 hasta 200 mg/5ml de ibuprofeno y uno o mas excipientes farmaceuticamente aceptables, util para tratar el dolor pre, peri o postoperatorio.
CA2814057C (en) * 2010-11-04 2022-02-01 Aft Pharmaceuticals Limited Intravenous composition comprising paracetamol and ibuprofen
JP5830412B2 (ja) 2011-03-02 2015-12-09 ライオン株式会社 水難溶性薬物と賦形剤との粉砕物の製造方法、造粒粒子の製造方法、錠剤の製造方法
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen

Also Published As

Publication number Publication date
GB2595406B (en) 2023-05-10
AU2019268077A1 (en) 2020-09-10
TN2021000176A1 (en) 2023-04-04
BR112021017037A2 (pt) 2021-11-09
EP3930691A1 (en) 2022-01-05
US20220175680A1 (en) 2022-06-09
AU2022201196A1 (en) 2022-03-17
UA127775C2 (uk) 2023-12-27
EP3930691A4 (en) 2022-11-30
MA62176A1 (fr) 2024-01-31
CN113795243A (zh) 2021-12-14
US11197830B2 (en) 2021-12-14
CO2021011525A2 (es) 2021-09-20
US20200268673A1 (en) 2020-08-27
ECSP21072036A (es) 2021-11-30
PE20220591A1 (es) 2022-04-22
EA202192118A1 (ru) 2021-11-18
AU2024203208A1 (en) 2024-05-30
MA54028B2 (fr) 2023-10-31
TW202045148A (zh) 2020-12-16
WO2020176736A1 (en) 2020-09-03
MA54028A1 (fr) 2022-06-30
CR20210451A (es) 2021-12-02
AU2021200634B2 (en) 2022-03-10
GB202112205D0 (en) 2021-10-13
MX2021010338A (es) 2022-01-07
US11872317B2 (en) 2024-01-16
AU2019268077B2 (en) 2021-02-25
US20240091160A1 (en) 2024-03-21
US20230201125A1 (en) 2023-06-29
SG11202109258WA (en) 2021-09-29
GB2595406A (en) 2021-11-24
JOP20210235A1 (ar) 2023-01-30
AU2021200634A1 (en) 2021-03-04
IL285866A (en) 2021-10-31
NZ759337A (en) 2023-06-30
US11534407B2 (en) 2022-12-27
CA3131917A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
CL2021002252A1 (es) Composición farmacéutica que comprende paracetamol e ibuprofeno
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
EA200501586A1 (ru) Фармацевтические продукты
ECSP024341A (es) Composiciones farmaceuticas
BRPI0512756A (pt) composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
DK1578406T3 (da) Farmaceutisk sammensætning med modificeret frigivelse
GT200600500A (es) Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
EP3965772A4 (en) PHARMACEUTICAL COMPOSITION BASED ON BREXANOLONE, GANAXOLONE OR ZURANOLONE, AND THEIR USE
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
HUP0401200A2 (hu) Terbinafint tartalmazó gyógyszerészeti összetételek és eljárás előállításukra
WO2006109175A3 (en) Solid dosage form of an antidiabetic drug
AR039232A1 (es) Una formulacion farmaceutica que comprende al menos un compuesto seleccionado del grupo formado por hipnoticos no barbituricos y no benzodiacepinicos, y melatonina
MXPA02010828A (es) Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.
AR067351A1 (es) Combinacion de picotamida con nafronil
EP3765072A4 (en) 3,5-DIALCOXYBENZOYL-3'-AMINO-3'-DEOXYADENOSINE-5'-TRIPHOSPHATE AND THEIR PHARMACEUTICAL USES THEREOF
TR2023017232A2 (tr) 5 mg ve 10 mg melatoni̇n i̇çeren farmasöti̇k formülasyonlar
UY27824A1 (es) Nueva formulación para la administración parenteral de crobenetina.
EA200601450A1 (ru) Новая комбинация агомелатина и тиморегулирующего средства и фармацевтические композиции, которые её содержат